Diabetes Start-Up Tethys Gets $25 Million To Speed Rollout Of Molecular Test
This article was originally published in The Pink Sheet Daily
Executive Summary
Real-world impact of predictive test questioned. Skeptics say patients at risk will be loath to change, test or no test.
You may also be interested in...
Companion Dx Pioneers Test Variety Of Business Models
Regulatory environment opens up, but alliances with Pharma have yet to take off.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.